The clinical performance of Green Spring®                                  SARS-CoV-2 antigen rapid test was determined                              in prospective, randomized, single-blind                                    studies. A total of 310 nasopharyngeal                                      specimens from symptomatic and asymptomatic                      patients were collected within 5 days of the onset of initial symptoms. The performance of the kit was compared with the results of a commercially available molecular test. The test was found to have a sensitivity of 98% and a specificity of 100.00%. The accuracy is 99.35%.